

AKR1A1 Antibody (C-Terminus)

Goat Polyclonal Antibody Catalog # ALS12442

Specification

AKR1A1 Antibody (C-Terminus) - Product Information

Application IHC, WB Primary Accession P14550

Reactivity Human, Mouse, Rat, Rabbit, Hamster,

Monkey, Pig, Horse, Xenopus, Bovine, Dog

Host Goat
Clonality Polyclonal
Calculated MW 37kDa KDa

AKR1A1 Antibody (C-Terminus) - Additional Information

Gene ID 10327

Other Names

Alcohol dehydrogenase [NADP(+)], 1.1.1.2, Aldehyde reductase, Aldo-keto reductase family 1 member A1, AKR1A1, ALDR1, ALR

Target/Specificity

Human AKR1A1. Both reported variants (NP_006057.1and NP_697021.1) represent identical protein

Reconstitution & Storage

Store at -20°C. Minimize freezing and thawing.

Precautions

AKR1A1 Antibody (C-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures.

AKR1A1 Antibody (C-Terminus) - Protein Information

Name AKR1A1

Synonyms ALDR1, ALR

Function

Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols. Displays enzymatic activity towards endogenous metabolites such as aromatic and aliphatic aldehydes, ketones, monosaccharides and bile acids, with a preference for negatively charged substrates, such as glucuronate and succinic semialdehyde (PubMed:10510318/a>). Functions as a detoxifiying enzyme by reducing a range of toxic aldehydes. Reduces methylglyoxal and 3-deoxyglucosone, which are present at elevated levels under hyperglycemic conditions and are cytotoxic. Involved also in the detoxification of lipid-derived aldehydes like acrolein (By similarity).



Plays a role in the activation of procarcinogens, such as polycyclic aromatic hydrocarbon trans-dihydrodiols, and in the metabolism of various xenobiotics and drugs, including the anthracyclines doxorubicin (DOX) and daunorubicin (DAUN) (PubMed:18276838, PubMed:11306097). Displays no reductase activity towards retinoids (By similarity).

Cellular Location

Cytoplasm, cytosol {ECO:0000250|UniProtKB:Q9JII6}. Apical cell membrane {ECO:0000250|UniProtKB:Q9JII6}

Tissue Location


Widely expressed. Highly expressed in kidney, salivary gland and liver. Detected in trachea, stomach, brain, lung, prostate, placenta, mammary gland, small intestine and lung

AKR1A1 Antibody (C-Terminus) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- <u>Immunofluorescence</u>
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

AKR1A1 Antibody (C-Terminus) - Images



Anti-AKR1A1 antibody IHC of human kidney.





HEK293 overexpressing AKR1A1 (RC200302) and probed with the antibody (mock transfection in first...

AKR1A1 Antibody (C-Terminus) - Background

Catalyzes the NADPH-dependent reduction of a variety of aromatic and aliphatic aldehydes to their corresponding alcohols. Catalyzes the reduction of mevaldate to mevalonic acid and of glyceraldehyde to glycerol. Has broad substrate specificity. In vitro substrates include succinic semialdehyde, 4- nitrobenzaldehyde, 1,2-naphthoquinone, methylglyoxal, and D- glucuronic acid. Plays a role in the activation of procarcinogens, such as polycyclic aromatic hydrocarbon trans-dihydrodiols, and in the metabolism of various xenobiotics and drugs, including the anthracyclines doxorubicin (DOX) and daunorubicin (DAUN).

AKR1A1 Antibody (C-Terminus) - References

Bohren K.M.,et al.J. Biol. Chem. 264:9547-9551(1989). Fujii J.,et al.Cytogenet. Cell Genet. 84:230-232(1999). Barski O.A.,et al.Genomics 60:188-198(1999).

Ota T., et al. Nat. Genet. 36:40-45(2004).

Ebert L., et al. Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.